Wellness & Lifestyle – Page 19

Advances in Graft-versus-Host Disease Prophylaxis: Cyclophosphamide and Cyclosporin in Allogeneic Stem Cell Transplantation

By MedXY 08/01/2025

Post-transplant cyclophosphamide plus cyclosporin significantly improves GVHD-free, relapse-free survival compared to standard prophylaxis in matched related donor stem cell transplantation.

Clinical Updates Wellness & Lifestyle

Multidose Ondansetron After Emergency Visits: Reducing Gastroenteritis Severity in Children

By MedXY 08/01/2025

A randomized trial shows that multidose ondansetron after pediatric ED visits for gastroenteritis reduces moderate-to-severe illness, though impact on vomiting duration and healthcare utilization is limited.

Clinical Updates Wellness & Lifestyle

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort

By MedXY 08/01/2025

A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.

Clinical Updates Wellness & Lifestyle

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial

By MedXY 07/31/2025

Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.

Clinical Updates Wellness & Lifestyle

Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data

By MedXY 07/31/2025

Phase 3 data show trastuzumab deruxtecan significantly improves survival over ramucirumab plus paclitaxel in HER2-positive metastatic gastric cancer, with manageable safety, supported by real-world evidence from Japan.

Clinical Updates Wellness & Lifestyle

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial

By MedXY 07/31/2025

Tarlatamab significantly improves overall survival and reduces severe adverse events compared to chemotherapy in patients with small-cell lung cancer progressing after platinum-based therapy.

Clinical Updates Wellness & Lifestyle

Acute Normovolemic Hemodilution in Cardiac Surgery: No Reduction in Allogeneic Transfusion—Insights from a Multinational Randomized Trial

By MedXY 07/31/2025

A large multinational trial found that acute normovolemic hemodilution (ANH) did not significantly reduce allogeneic red-cell transfusion in adult cardiac surgery patients, with similar safety outcomes compared to usual care.

Clinical Updates Wellness & Lifestyle

FDA Approves Once-Weekly Skytrofa (Lonapegsomatropin-tcgd) for Adult Growth Hormone Deficiency: Clinical Implications and Evidence Review

By MedXY 07/31/2025

Skytrofa, a once-weekly injectable growth hormone, is FDA-approved for adult GHD, offering improved adherence and positive metabolic outcomes. Clinical trials show superior efficacy and favorable safety compared to daily somatropin.

Clinical Updates Wellness & Lifestyle

Dupilumab as a Steroid-Sparing Strategy for ADC-Induced Skin Toxicities: Enhancing Cancer Therapy Continuity

By MedXY 07/31/2025

Dupilumab controls ADC-related skin toxicities more effectively than systemic steroids, reducing cancer treatment discontinuation and improving response rates.

Clinical Updates Wellness & Lifestyle

Ivosidenib Plus Azacitidine Significantly Improves Survival in IDH1-Mutated AML: Long-Term Results from the AGILE Study

By MedXY 07/31/2025

The AGILE trial shows ivosidenib plus azacitidine more than triples median overall survival in newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy, with improved hematologic recovery and safety.